Smith N - Search Results

1

Effects of oral sepiapterin on blood Phe concentration in a broad range of patients with phenylketonuria (APHENITY): results of an international, phase 3, randomised, double-blind, placebo-controlled trial.

Muntau AC, Longo N, Ezgu F, Schwartz IVD, Lah M, Bratkovic D, Margvelashvili L, Kiykim E, Zori R, Campistol Plana J, Bélanger-Quintana A, Lund A, Guilder L, Chakrapani A, Mungan HN, Guimas A, Cabrales Guerra IDC, MacDonald A, Ingalls K, Smith N; APHENITY study group. Muntau AC, et al. Among authors: smith n. Lancet. 2024 Oct 5;404(10460):1333-1345. doi: 10.1016/S0140-6736(24)01556-3. Lancet. 2024. PMID: 39368841 Clinical Trial.

2

Phase I clinical evaluation of CNSA-001 (sepiapterin), a novel pharmacological treatment for phenylketonuria and tetrahydrobiopterin deficiencies, in healthy volunteers.

Smith N, Longo N, Levert K, Hyland K, Blau N. Smith N, et al. Mol Genet Metab. 2019 Apr;126(4):406-412. doi: 10.1016/j.ymgme.2019.02.001. Epub 2019 Feb 10. Mol Genet Metab. 2019. PMID: 30922814 Clinical Trial.

3

Exploratory study of the effect of one week of orally administered CNSA-001 (sepiapterin) on CNS levels of tetrahydrobiopterin, dihydrobiopterin and monoamine neurotransmitter metabolites in healthy volunteers.

Smith N, Longo N, Levert K, Hyland K, Blau N. Smith N, et al. Mol Genet Metab Rep. 2019 Aug 12;21:100500. doi: 10.1016/j.ymgmr.2019.100500. eCollection 2019 Dec. Mol Genet Metab Rep. 2019. PMID: 31453106 Free PMC article.

4

Effect of Oral CNSA-001 (sepiapterin, PTC923) on gastric accommodation in women with diabetic gastroparesis: A randomized, placebo-controlled, Phase 2 trial.

Abell TL, Garcia LM, Wiener GJ, Wo JM, Bulat RS, Smith N. Abell TL, et al. Among authors: smith n. J Diabetes Complications. 2021 Sep;35(9):107961. doi: 10.1016/j.jdiacomp.2021.107961. Epub 2021 Jun 17. J Diabetes Complications. 2021. PMID: 34176722 Free article. Clinical Trial.

5

PTC923 (sepiapterin) lowers elevated blood phenylalanine in subjects with phenylketonuria: a phase 2 randomized, multi-center, three-period crossover, open-label, active controlled, all-comers study.

Bratkovic D, Margvelashvili L, Tchan MC, Nisbet J, Smith N. Bratkovic D, et al. Among authors: smith n. Metabolism. 2022 Mar;128:155116. doi: 10.1016/j.metabol.2021.155116. Epub 2021 Dec 29. Metabolism. 2022. PMID: 34973284 Free article. Clinical Trial.

6

Validation and application of volumetric absorptive microsampling (VAMS) dried blood method for phenylalanine measurement in patients with phenylketonuria.

Gao L, Smith N, Kaushik D, Milner S, Kong R. Gao L, et al. Among authors: smith n. Clin Biochem. 2023 Jun;116:65-74. doi: 10.1016/j.clinbiochem.2023.03.012. Epub 2023 Mar 30. Clin Biochem. 2023. PMID: 37001750 Free article.

7

Relative Oral Bioavailability and Food Effects of Two Sepiapterin Formulations in Healthy Participants.

Gao L, Kaushik D, Xia Y, Ingalls K, Milner S, Smith N, Kong R. Gao L, et al. Among authors: smith n. Clin Pharmacol Drug Dev. 2024 May;13(5):506-516. doi: 10.1002/cpdd.1363. Epub 2023 Dec 29. Clin Pharmacol Drug Dev. 2024. PMID: 38156759 Clinical Trial.

8

Clinical Assessment of Breast Cancer Resistance Protein (BCRP)-Mediated Drug-Drug Interactions of Sepiapterin with Curcumin and Rosuvastatin in Healthy Volunteers.

Gao L, Kaushik D, Ingalls K, Milner S, Smith N, Kong R. Gao L, et al. Among authors: smith n. Drugs R D. 2024 Sep;24(3):477-487. doi: 10.1007/s40268-024-00488-0. Epub 2024 Sep 24. Drugs R D. 2024. PMID: 39316278 Free PMC article. Clinical Trial.

9

A Phase 1 Study to Assess the Pharmacokinetics, Food Effect, Safety, and Tolerability of Sepiapterin in Healthy Japanese and Non-Japanese Participants.

Gao L, Kaushik D, Ingalls K, Smith N, Kong R. Gao L, et al. Among authors: smith n. Pharmaceuticals (Basel). 2024 Oct 22;17(11):1411. doi: 10.3390/ph17111411. Pharmaceuticals (Basel). 2024. PMID: 39598323 Free PMC article.

10

CXCR1 Expression in MDA-PCa-2b Cell Upregulates ITM2A to Inhibit Tumor Growth.

Adekoya TO, Smith N, Kothari P, Dacanay MA, Li Y, Richardson RM. Adekoya TO, et al. Among authors: smith n. Cancers (Basel). 2024 Dec 11;16(24):4138. doi: 10.3390/cancers16244138. Cancers (Basel). 2024. PMID: 39766038

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

5,966 results

Search Page

Filters